신부전 치료 시장 규모, 점유율 및 동향 분석 보고서 : 치료별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Renal Failure Treatment Market Growth & Trends:

The global renal failure treatment market size is anticipated to reach USD 197.1 billion by 2030 and is anticipated to grow at a CAGR of 8.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of products and services designed to manage and treat chronic kidney disease (CKD) and end-stage renal disease (ESRD).

The increasing prevalence of chronic kidney disease is a significant market driver. The growing incidence is largely attributed to the rising rates of diabetes and hypertension, which are known risk factors for kidney disease. As the population ages and these chronic conditions become more prevalent, the need for renal failure treatment continues to grow, placing additional pressure on healthcare systems to provide adequate care.

Rising awareness and education about kidney health are crucial market drivers. Public health campaigns and initiatives aimed at educating individuals about the risks and symptoms of kidney disease have contributed to earlier diagnosis and treatment. The heightened awareness encourages patients to seek medical advice sooner, ultimately leading to timely interventions and improved management of kidney conditions.

In October 2023, Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) entered a licensing agreement to co-commercialize Desidustat, the first oral drug in India to treat anemia caused by chronic kidney disease (CKD). The licensing agreement for Desidustat represents a significant development in the market by providing a novel oral treatment option for anemia associated with CKD, enhancing patient care, and expanding market access in India.

Renal Failure Treatment Market Report Highlights:

• Based on treatment, dialysis dominated the market with the largest revenue share of 72.34% in 2023. The rising prevalence of CKD and ESRD is driving the demand for renal replacement therapies. Major factors contributing to this trend include an aging population, technological advancements in dialysis, and increased kidney health awareness
• Based on end-use, hospitals dominated the market with the largest revenue share of 57.64% in 2023. Factors driving this growth include a rise in patient admissions for dialysis and transplant procedures, technological advancements in renal care equipment, and comprehensive healthcare services provided by hospitals that cater to complex cases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Renal Failure Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increased prevalence of CKD
    • 3.2.1.2. Advancements in treatment technologies
    • 3.2.1.3. Rising awareness and education about kidney health
    • 3.2.1.4. Aging population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Limited Healthcare Resources and Access
• 3.3. Renal Failure Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Renal Failure Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Renal Failure Treatment Market: Treatment Dashboard
• 4.2. Global Renal Failure Treatment Market: Treatment Movement Analysis
• 4.3. Global Renal Failure Treatment Market by Treatments, Revenue
• 4.4. Dialysis
  • 4.4.1. Dialysis market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Hemodialysis
    • 4.4.2.1. Hemodialysis market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. Peritoneal Dialysis
    • 4.4.3.1. Peritoneal Dialysis market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Kidney Transplantation
  • 4.5.1. Kidney transplantation market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Drug Therapy
  • 4.6.1. Drug therapy market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.2. Antihypertensive Drugs
    • 4.6.2.1. Antihypertensive Drugs market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.3. Antianemia Therapeutics (Erythropoiesis-Stimulating Agents)
    • 4.6.3.1. Antianemia therapeutics (Erythropoiesis-Stimulating Agents) market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.4. Potassium Binders
    • 4.6.4.1. Potassium Binders market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6.5. Phosphate Binders
    • 4.6.5.1. Phosphate Binders market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Renal Failure Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Global Renal Failure Treatment Market: End Use Dashboard
• 5.2. Global Renal Failure Treatment Market: End Use Movement Analysis
• 5.3. Global Renal Failure Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty clinics market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Renal Failure Treatment Market: Regional Estimates & Trend Analysis by Treatment, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. NIPRO
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Fresenius Medical Care AG
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Baxter
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Medtronic
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. B. Braun SE
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Asahi Kasei Medical Co., Ltd.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. AbbVie Inc.
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Nikkiso Co., Ltd.
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. JMS Co., Ltd.
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. AstraZeneca
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives